Called the Tapestri Solution for Solid Tumor Research, the new single-cell DNA sequencing workflow features an enhanced nuclei isolation protocol for both fresh and fresh frozen samples; predesigned research panels for breast cancer and glioblastoma multiforme; and an enhanced single-cell copy number variation bioinformatic analysis tool, according to the vendor.

In a related development, Mission Bio has opened its first Center of Excellence at Memorial Sloan Kettering Cancer Center to drive best practices for solid tumor single-cell DNA profiling.

Mission Bio announces its 1st single-cell Tapestri Center of Excellence
Mission Bio has announced its first Center of Excellence, located at Memorial Sloan Kettering Cancer Center (MSK). As the first single-cell Tapestri Center...

Mission Bio transfers 1st Tapestri GMP-ready CGT assay
Mission Bio has completed the first tech transfer of a clinical trial-, good manufacturing practices (GMP)-ready cell and gene therapy (CGT) assay from...

Mission Bio touts study about its Tapestri platform
Mission Bio announced that its Tapestri platform helped elucidate resistance mechanisms to lung cancer drugs. Researchers from Memorial Sloan Kettering...

Mission Bio debuts new capabilities for cell, gene therapy
Mission Bio has unveiled its Tapestri Cell & Gene Therapy Solutions, a new addition to its Tapesti platform that can provide analytical characterization...

Mission Bio updates platform to expand heme-onc research
Mission Bio has improved its Tapestri platform to expand its accessibility and utility in hematologic oncology (heme-onc) research.